# Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

> **NCT00918385** · PHASE2 · TERMINATED · sponsor: **Duke University** · enrollment: 57 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Nilutamide
- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT00918385
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-05
- **Primary completion:** 2012-02
- **Final completion:** 2013-08
- **Target enrollment:** 57 (ACTUAL)
- **Why stopped:** Permanent closure of trial to further accrual based on IDE disapproval
- **Last updated:** 2014-10-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00918385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00918385, "Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00918385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*